Randomized phase II study of FOLFIRI plus ramucirumab versus FOLFOXIRI plus ramucirumab as first-line treatment for metastatic colorectal cancer: WJOG9216G (RECAST)

20260 citationsJournal Article

Authors

Good health and well-being

Published in: European Journal of Cancer

Volume 238, pp. 116688-116688

Field-Weighted Citation Impact: 0.00